Ross Moat
Corporate Officer/Principal bei KINIKSA PHARMACEUTICALS, LTD.
Vermögen: 286 620 $ am 30.04.2024
Profil
Ross Moat is currently the Chief Commercial Officer at Kiniksa Pharmaceuticals Ltd.
He previously worked as the General Manager at Synageva BioPharma Corp.
and as the VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. Mr. Moat completed his undergraduate degree at Middlesex University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
08.04.2024 | 16 276 ( 0,04% ) | 286 620 $ | 30.04.2024 |
Aktive Positionen von Ross Moat
Unternehmen | Position | Beginn |
---|---|---|
KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01.02.2021 |
Ehemalige bekannte Positionen von Ross Moat
Unternehmen | Position | Ende |
---|---|---|
AVEXIS INC | Vertrieb & Marketing | 01.06.2019 |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
Ausbildung von Ross Moat
Middlesex University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
Private Unternehmen | 2 |
---|---|
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |